June 9th, 2014
Selections from Richard Lehman’s Literature Review: June 9th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the CORONARY trial, the association of azithromycin with mortality and CV events among older patients hospitalized with pneumonia, and more.
October 7th, 2011
FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin
Larry Husten, PHD
The FDA has approved a fixed-dose combination tablet consisting of sitagliptin and simvastatin, two drugs previously approved for type 2 diabetes and hypercholesterolemia. Merck will market the new drug as Juvisync. “This is the first product to combine a type 2 diabetes drug with a cholesterol lowering drug in one tablet,” said Mary H. Parks, the […]
January 14th, 2011
Combination Therapy Beats Single Therapy As Initial Antihypertensive Therapy
Larry Husten, PHD
In the ACCELERATE (Aliskiren and the calcium channel blocker amlopdipine combination as an initial treatment strategy for hypertension control) trial, more than 1200 patients with early essential hypertension were randomized to either aliskiren, amlodipine, or the combination of the two drugs for 4 months. The results, which have been published online in the Lancet, showed […]
NEJM Journal Watch — Recent Cardiology Articles- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Session 2024